Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

US FDA cut first-cycle review time 46% between fiscal year 2013 and FY 2015, but more than 900 ANDAs still awaited review by end of 2016.

FDA entrance sign 2016

The US FDA has dramatically improved its generic drug application review times, but still had about one-third of all applications submitted still pending at the end of 2016.

A Government Accountability Office report on the generic drug user fee program released in June found that the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Biosimilars & Generics